Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients?

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.

The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.

This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.

Inclusion Criteria:

• Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
• Patients who are already in therapeutic education program ETPARK,
• Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
• Patients with health insurance,
• Patients who have signed a written informed consent form.

Exclusion Criteria:

• Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
• Patients who has already done workshop on Parkinson disease drug (program ETPARK)
• Patients already included in clinical trial during the study,
• Patients who have severe psychiatric disorders or dopaminergic psychosis,
• Patients with cognitive impairment,
• Patients unable to complete the various scales used in the study,
• Patients under juridical protection,
• Women pregnant or breastfeeding.